Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 11, 2013

Primary Completion Date

January 17, 2030

Study Completion Date

January 17, 2030

Conditions
Hemophilia B
Interventions
BIOLOGICAL

AskBio009

Single dose IV injection

Trial Locations (15)

10029

Mount Sinai Medical Center, New York

29425

Medical University of South Carolina, Charleston

30322

Emory University, Atlanta

53226

BloodCenter of Wisconsin, Milwaukee

55455

University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute, Minneapolis

60612

Rush University Medical Center, Chicago

77030

Gulf States Hemophilia and Thrombosis Center, Houston

80045

U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center, Aurora

90007

Orthopaedic Hemophilia Treatment Center, Los Angeles

90027

Children's Hospital Los Angeles, Los Angeles

95817

University of California Davis Medical Center, Sacramento

97239

The Hemophilia Center, Oregon Health and Science University, Portland

98104

Bloodworks Northwest, Seattle

92103-8651

University of California at San Diego Medical Center, San Diego

022105

Children's Hospital of Boston, Boston

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT01687608 - Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B | Biotech Hunter | Biotech Hunter